Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes
Dhaval Dixit, … , Jordan E. Axelrad, Susan R. Schwab
Dhaval Dixit, … , Jordan E. Axelrad, Susan R. Schwab
Published January 9, 2024
Citation Information: J Clin Invest. 2024;134(4):e174984. https://doi.org/10.1172/JCI174984.
View: Text | PDF
Research Article Immunology

S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes

  • Text
  • PDF
Abstract

Effective immunity requires a large, diverse naive T cell repertoire circulating among lymphoid organs in search of antigen. Sphingosine 1-phosphate (S1P) and its receptor S1PR1 contribute by both directing T cell migration and supporting T cell survival. Here, we addressed how S1P enables T cell survival and the implications for patients treated with S1PR1 antagonists. We found that S1PR1 limited apoptosis by maintaining the appropriate balance of BCL2 family members via restraint of JNK activity. Interestingly, the same residues of S1PR1 that enable receptor internalization were required to prevent this proapoptotic cascade. Findings in mice were recapitulated in ulcerative colitis patients treated with the S1PR1 antagonist ozanimod, and the loss of naive T cells limited B cell responses. Our findings highlighted an effect of S1PR1 antagonists on the ability to mount immune responses within lymph nodes, beyond their effect on lymph node egress, and suggested both limitations and additional uses of this important class of drugs.

Authors

Dhaval Dixit, Victoria M. Hallisey, Ethan Y.S. Zhu, Martyna Okuniewska, Ken Cadwell, Jerry E. Chipuk, Jordan E. Axelrad, Susan R. Schwab

×

Figure 8

S1PR1 modulators impair T cell survival in mice and humans.

Options: View larger image (or click on image) Download as PowerPoint
S1PR1 modulators impair T cell survival in mice and humans.
(A–D): (A) W...
(A–D): (A) WT mice were treated with 1 mg/kg FTY720 or vehicle every other day for 3 weeks, and naive CD4+ T cells in LNs were analyzed by flow cytometry. (B) Frequency ActCasp+ annexin V+ and PI+ among naive CD4+ T cells in LNs. Compilation of 3 experiments, 9–10 per group. (C) Relative MFI for p-MKK7 and p-JNK. Relative MFI represents MFI in 1 mouse divided by the mean for controls in that experiment. p-MKK7: compilation of 2 experiments, 4–6 per group; p-JNK: compilation of 3 experiments, 6–9 per group. (D) Relative MFI for BCL2, PUMA, and BAX. Compilation of 3 experiments, 6–9 per group. (E–H): (E) PBMCs were isolated from UC patients treated with ozanimod (UC+Oza), UC patients not treated with ozanimod (UC), or healthy controls (HC), and analyzed by flow cytometry. (F) Frequency annexin V+ among naive CD4+ T cells. Compilation of 10 experiments, 8–11 per group. (G) Representative histograms and compilations of p-JNK and p-MKK7 relative MFI for naive CD4+ T cells. Relative MFI represents MFI in 1 sample divided by the mean for the indicated comparison group on that day. Left column: UC patients not treated with ozanimod versus healthy controls. Middle column: UC patients treated with ozanimod versus healthy controls. Right column: UC patients treated with ozanimod versus UC patients not treated with ozanimod. Each UC patient with ozanimod is represented once; if there was a choice between comparing that patient with a healthy control and comparing him or her with a UC patient not taking ozanimod, he or she was compared with the UC patient not taking ozanimod. Compilation of 10 experiments, 3–7 per group. (H) Representative histograms and compilation of relative MFI for BCL2 and PUMA. Compilation of 10 experiments, 3–7 per group. B–D, Student’s t test; F–H, 1-way ANOVA with multiple comparisons. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts